Target intelligence / Profile preview

Succinate dehydrogenase [ubiquinone] iron-sulfur subunit (SDHB)

Target
SDHB
Molecular classification
Enzyme, Oxidoreductase, Mitochondrial respiratory chain complex II
01

Overview

The Succinate dehydrogenase [ubiquinone] iron-sulfur subunit (SDHB) is a nuclear-encoded component of the mitochondrial respiratory chain complex II, which serves as a vital link between the citric acid cycle and the electron transport chain. It functions by facilitating the transfer of electrons from succinate-derived FADH2 to ubiquinone through its three distinct iron-sulfur clusters (UniProt: P21912). Beyond its fundamental role in energy production, SDHB is recognized as a potent tumor suppressor; germline mutations in this subunit are a primary cause of hereditary paraganglioma-pheochromocytoma syndromes (PubMed: 11823443). Loss of SDHB function leads to the pathological accumulation of succinate, an oncometabolite that inhibits alpha-ketoglutarate-dependent dioxygenases, thereby promoting angiogenesis and epigenetic dysregulation (PubMed: 15660115). In the pharmaceutical context, while SDHB is a major target for agricultural fungicides known as SDHIs, it is increasingly investigated in human medicine as a biomarker for SDH-deficient cancers, including specific subtypes of gastrointestinal stromal tumors and renal cell carcinomas (PubMed: 21893128). Therapeutic strategies currently focus on exploiting the metabolic dependencies created by SDHB deficiency or identifying small molecules that can modulate mitochondrial respiration in metabolic diseases (PubMed: 28605213).

Other names
Succinate dehydrogenase complex subunit BIron-sulfur subunit of complex IISDH2SDHIPCWS2PGL4
02

Mechanism of action

Inhibition of the succinate binding site or the ubiquinone binding site within the mitochondrial respiratory chain complex II, preventing electron transfer and succinate oxidation.

03

Biological functions

Citric acid cycleElectron transport chainSuccinate oxidationUbiquinone reductionIron-sulfur cluster binding
04

Disease associations

ParagangliomaPheochromocytomaGastrointestinal stromal tumorRenal cell carcinomaLeigh syndromeCowden-like syndrome
05

Safety considerations

Mitochondrial toxicityPotential for secondary tumorigenesis due to its role as a tumor suppressorMetabolic acidosisNeurological impairmentLactic acidosis
06

Interacting drugs

Malonate

5 more in the full profile.

07

Biomarkers

SDHB protein expression loss (via immunohistochemistry)Succinate-to-fumarate ratioSDHB germline mutation statusHIF-1 alpha stabilizationPlasma methoxytyramine levels

Beyond the preview

Go deeper on Succinate dehydrogenase [ubiquinone] iron-sulfur subunit (SDHB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Succinate dehydrogenase [ubiquinone] iron-sulfur subunit (SDHB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call